drugset / Trial / NCT01533948
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Phase 2
Terminated
25 enrolled
Roswell Park Cancer Institute
National Cancer Institute (NCI) · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | — | Oral |